TruAlt Bioenergy Approves Q1 FY27 Audited Results, Revenue at ₹626.88 Crore
TruAlt Bioenergy Limited's Board approved audited standalone and consolidated financial results for Q1 FY27. Consolidated revenue from operations reached ₹626.88 crore, up from ₹303.89 crore in Q1 FY26. Profit after tax was ₹59.27 crore, significantly higher than ₹4.73 crore in the prior year.
The significant year-on-year growth in revenue and profit is a material development for investors and the market.
The company reported a substantial increase in revenue and profit for the quarter ended June 30, 2026, compared to the same period last year.
TruAlt Bioenergy Limited announced the outcome of its Board Meeting held on July 28, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. The financial results were recommended by the Audit Committee and approved by the Board.
The consolidated revenue from operations for the quarter stood at ₹62,688.31 lakh (₹626.88 crore), an increase from ₹30,389.17 lakh (₹303.89 crore) in the corresponding quarter of the previous year. Total income for the quarter was ₹64,140.79 lakh (₹641.41 crore). Profit before tax for the quarter was ₹7,844.56 lakh (₹78.45 crore), compared to ₹579.95 lakh (₹5.80 crore) in the same period last year. Profit for the period after tax was ₹5,927.14 lakh (₹59.27 crore), a significant rise from ₹472.52 lakh (₹4.73 crore) in Q1 FY26.
The standalone revenue from operations for the quarter was ₹61,592.17 lakh (₹615.92 crore). Profit before tax for the standalone results was ₹7,331.09 lakh (₹73.31 crore), and profit for the period after tax was ₹5,500.64 lakh (₹55.01 crore).
The company's business primarily involves the manufacturing and selling of ethanol and compressed biogas. The meeting commenced at 2:30 p.m. (IST) and concluded at 6:15 p.m. (IST). The financial results and the Limited Review Report will be published in newspapers and will also be available on the company's website.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.